Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies

Transplantation and Cellular Therapy(2020)10.1016/j.jtct.2020.12.020Source: DataRank Database

Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies is a research paper published in Transplantation and Cellular Therapy (2020). On theSindex it has a DataRank of 0. It has been cited 10 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

10 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 1.03)OA: closedTopics (37)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (22)

Dongyun Yang ORCID,Monzr M. Al Malki ORCID,Matthew Mei ORCID,Sally Mokhtari,Andrew Artz ORCID

Live enrichment

PubMed:33781525 OpenAlex:https://openalex.org/W3113994324

National Institutes of Health

Grant: P30 CA033572

Celgene

Kao Corporation

FWCI

1.03

Citation Percentile

0.8%

Citation Trend

2022

2023

2025

closedLicense: http://creativecommons.org/licenses/by-nc-nd/4.0/

publisherhttps://api.elsevier.com/content/article/PII:S2666636720300944?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666636720300944?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jtct.2020.12.020

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33781525

Fields of Study

Acute Lymphoblastic Leukemia researchChronic Myeloid Leukemia TreatmentsCAR-T cell therapy researchAdultB-LymphocytesHematopoietic Stem Cell TransplantationHumansPrecursor Cell Lymphoblastic Leukemia-LymphomaRetrospective StudiesSalvage Therapy

MeSH Terms

AdultB-LymphocytesHumansRetrospective StudiesSalvage TherapyHematopoietic Stem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Keywords

BlinatumomabSalvage therapyMedicineHazard ratioInternal medicineTransplantationHematopoietic stem cell transplantationRefractory (planetary science)GastroenterologyOncologySurgeryConfidence intervalChemotherapyLeukemiaLymphoblastic LeukemiaBiologyAcute lymphoblastic leukemiaAllogeneic Hematopoietic Cell TransplantationInotuzumabPhiladelphia Negative

Sustainable Development Goals

SDG 0: Good health and well-being

Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies

FAIR Checklist

Authors (22)

Funding (3 grants)

Impact

Open Access

Topics